207 related articles for article (PubMed ID: 19786600)
1. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
Mann PA; McNicholas PM; Chau AS; Patel R; Mendrick C; Ullmann AJ; Cornely OA; Patino H; Black TA
Antimicrob Agents Chemother; 2009 Dec; 53(12):5026-34. PubMed ID: 19786600
[TBL] [Abstract][Full Text] [Related]
2. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
González GM; Elizondo M; Ayala J
J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
[TBL] [Abstract][Full Text] [Related]
3. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.
Panackal AA; Gribskov JL; Staab JF; Kirby KA; Rinaldi M; Marr KA
J Clin Microbiol; 2006 May; 44(5):1740-3. PubMed ID: 16672401
[TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
7. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
Wong-Beringera A; Hindler J; Brankovic L; Muehlbauer L; Steele-Moore L
Diagn Microbiol Infect Dis; 2001 Jan; 39(1):25-31. PubMed ID: 11173188
[TBL] [Abstract][Full Text] [Related]
8. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
Lindberg E; Hammarström H; Ataollahy N; Kondori N
Sci Rep; 2019 Mar; 9(1):3838. PubMed ID: 30846717
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.
Borman AM; Muller J; Walsh-Quantick J; Szekely A; Patterson Z; Palmer MD; Fraser M; Johnson EM
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182537
[TBL] [Abstract][Full Text] [Related]
10. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
Magill SS; Shields C; Sears CL; Choti M; Merz WG
J Clin Microbiol; 2006 Feb; 44(2):529-35. PubMed ID: 16455909
[TBL] [Abstract][Full Text] [Related]
11. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
12. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
Lei J; Xu J; Wang T
J Mycol Med; 2018 Jun; 28(2):310-313. PubMed ID: 29685520
[TBL] [Abstract][Full Text] [Related]
14. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.
Sojakova M; Liptajova D; Borovsky M; Subik J
Mycopathologia; 2004 Feb; 157(2):163-9. PubMed ID: 15119851
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
[TBL] [Abstract][Full Text] [Related]
16. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).
Safdar A; Chaturvedi V; Koll BS; Larone DH; Perlin DS; Armstrong D
Antimicrob Agents Chemother; 2002 Oct; 46(10):3268-72. PubMed ID: 12234857
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Drago M; Scaltrito MM; Morace G;
Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
[TBL] [Abstract][Full Text] [Related]
18. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
19. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
[TBL] [Abstract][Full Text] [Related]
20. The patterns of colonization and antifungal susceptibility of Candida, isolated from preterm neonates in Khorramabad, South West of Iran.
Kooshki P; Rezaei-Matehkolaei A; Mahmoudabadi AZ
J Mycol Med; 2018 Jun; 28(2):340-344. PubMed ID: 29530715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
